Ocular Therapeutix Inc. Stock
€10.73
Your prediction
Ocular Therapeutix Inc. Stock
Pros and Cons of Ocular Therapeutix Inc. in the next few years
Pros
Cons
Performance of Ocular Therapeutix Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ocular Therapeutix Inc. | 2.830% | 4.892% | 4.078% | 34.269% | 33.833% | 101.655% | 45.850% |
| SI-BONE Inc | 0.000% | 2.174% | -6.623% | -3.425% | 8.462% | - | - |
| Orasure Tech | - | 10.236% | 1.449% | -31.034% | -18.129% | -30.693% | -70.984% |
| scPharmaceuticals | -0.520% | 0.915% | 9.405% | 2.889% | 42.901% | -19.478% | -33.381% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When delving into the financials of Ocular (NASDAQ: OCUL) in the healthcare equipment and supplies industry, the analysis reveals a company facing significant challenges, evidenced by a bleak profitability outlook and a troubling balance sheet. The indicators present a mixed scenario, where potential exists amidst considerable financial hurdles.
Market Capitalization: Ocular holds a market capitalization of approximately $1.21 billion. This sizeable market cap suggests that the company has gained investor confidence, likely due to prospects in the healthcare domain, which can often provide robust growth opportunities.
Revenue Growth: There is a notable quarterly revenue growth year-over-year (YOY) of 10.5%. This figure indicates a positive trajectory, suggesting that the company's sales efforts and product reception in the market are gaining traction. Moreover, the total revenue reported was around $59.84 million, which, despite being modest, shows movement in the right direction.
Comments
News
OCUL Sales Drop 18%
Ocular Therapeutix (NASDAQ:OCUL), a biotechnology company developing therapies for eye diseases, reported its second quarter results on August 5, 2025. The earnings release pointed to a significant
Why Ocular Therapeutix Was Bumping Higher This Week
The market was seeing Ocular Therapeutix (NASDAQ: OCUL) very positively this week, and that sunny view pushed the company's stock higher.
As of Friday morning before market open, the eye care